These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19903376)

  • 21. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers.
    Cryer B; Berlin RG; Cooper SA; Hsu C; Wason S
    Clin Ther; 2005 Feb; 27(2):185-91. PubMed ID: 15811481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
    Fuchs I; Spiel AO; Frossard M; Derhaschnig U; Riedmüller E; Jilma B
    Crit Care Med; 2010 Jun; 38(6):1423-9. PubMed ID: 20400900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
    Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
    J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
    Ohmori T; Yatomi Y; Nonaka T; Kobayashi Y; Madoiwa S; Mimuro J; Ozaki Y; Sakata Y
    J Thromb Haemost; 2006 Jun; 4(6):1271-8. PubMed ID: 16706971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
    J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
    Undas A; Placzkiewicz-Jankowska E; Zieliński L; Tracz W
    Thromb Haemost; 2007 Jun; 97(6):1056-8. PubMed ID: 17549314
    [No Abstract]   [Full Text] [Related]  

  • 27. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.
    Adamopoulos AB; Sakizlis GN; Nasothimiou EG; Anastasopoulou I; Anastasakou E; Kotsi P; Karafoulidou A; Stergiou GS
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):163-8. PubMed ID: 19568178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients.
    Perunicic-Pekovic G; Pljesa S; Rasic-Milutinovic Z; Stankovic S; Ilic M; Maletic R
    Can J Physiol Pharmacol; 2008 Apr; 86(4):205-9. PubMed ID: 18418430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of obesity on platelet reactivity and response to low-dose aspirin.
    Bordeaux BC; Qayyum R; Yanek LR; Vaidya D; Becker LC; Faraday N; Becker DM
    Prev Cardiol; 2010; 13(2):56-62. PubMed ID: 20377806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome.
    Zeugmann S; Quante A; Heuser I; Schwarzer R; Anghelescu I
    J Clin Psychiatry; 2010 Aug; 71(8):1007-16. PubMed ID: 20156411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
    Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
    J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose enteric-coated aspirin as an antiplatelet preparation.
    McLeod LJ; Roberts MS; Seville PR
    Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
    [No Abstract]   [Full Text] [Related]  

  • 33. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100.
    Homoncik M; Jilma B; Hergovich N; Stohlawetz P; Panzer S; Speiser W
    Thromb Haemost; 2000 Feb; 83(2):316-21. PubMed ID: 10739392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet activation in patients with colorectal cancer.
    Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
    Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
    Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inflammatory markers and cytokines in cardiovascular disease].
    Ogiwara F; Takahashi M; Ikeda U
    Rinsho Byori; 2004 Aug; 52(8):686-92. PubMed ID: 15478624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Safety of reintroducing platelet-inhibitory doses of aspirin in patients with urticaria or angioedema induced by anti-inflammatory doses].
    Vial A; Mathelier-Fusade P; Gaouar H; Leynadier F; Chosidow O; Aractingi S; Francès C
    Ann Dermatol Venereol; 2009 Jan; 136(1):15-20. PubMed ID: 19171224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors.
    Broekhuizen LN; van Wijk DF; Vink H; Stalmach A; Crozier A; Hutten BA; Kastelein JJ; Hugenholtz PG; Koenig W; Stroes ES
    Br J Nutr; 2011 Nov; 106(9):1416-22. PubMed ID: 21733322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.